CD44细胞
癌症研究
纳米载体
内化
甲状腺间变性癌
甲状腺球蛋白
甲状腺
透明质酸
体内
甲状腺癌
靶向治疗
化学
体外
医学
药物输送
纳米技术
材料科学
甲状腺癌
癌症
生物
细胞
内科学
生物化学
生物技术
解剖
作者
Shuo Huang,Linlin Zhang,Miaomiao Xu,Chao Li,Hongliang Fu,Jie Huang,Xin Jin,Sheng Liang,Hui Wang
标识
DOI:10.1002/adhm.202001029
摘要
Abstract New radionuclide‐labeled targeting nanocarrier systems have generated new opportunities for tumor treatment and imaging. Nevertheless, such therapeutic strategy is clinically unfeasible on anaplastic thyroid carcinoma (ATC) patients, because of lacking suitable targets and resistance to radiation. In order to figure out a potential treatment, immuno‐histochemical staining is performed in human ATC tissue species and high expression of cluster determinant 44 (CD44) is found. Therefore, a CD44‐targeted delivery system is designed and constructed by self‐assembly of tyrosine (Tyr)–hyaluronic acid (HA)–polyethyleneimine (PEI), which can radiolabel 131/125 I and load a p53 mutant restoring regent, Prima‐1. The 125 I‐labeled nanocomposites display an impressive tumor imaging as well as a long radiation treatment cycle. The 131 I‐labeled nanoparticles show remarkable anti ATC‐tumor effects in vitro and in vivo, due to radiosensitization of Prima‐1 by reactivation of the p53 mutants.
科研通智能强力驱动
Strongly Powered by AbleSci AI